Price T Rowe Associates Inc. MD Has $15.98 Million Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Price T Rowe Associates Inc. MD lowered its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 13.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,144,747 shares of the company's stock after selling 347,466 shares during the quarter. Price T Rowe Associates Inc. MD owned 3.14% of EyePoint Pharmaceuticals worth $15,980,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Franklin Resources Inc. grew its stake in shares of EyePoint Pharmaceuticals by 3.1% in the 4th quarter. Franklin Resources Inc. now owns 4,137,567 shares of the company's stock valued at $30,825,000 after purchasing an additional 125,519 shares during the period. Vanguard Group Inc. raised its stake in EyePoint Pharmaceuticals by 24.8% during the fourth quarter. Vanguard Group Inc. now owns 3,803,227 shares of the company's stock worth $28,334,000 after acquiring an additional 755,045 shares in the last quarter. Federated Hermes Inc. lifted its holdings in shares of EyePoint Pharmaceuticals by 92.7% during the fourth quarter. Federated Hermes Inc. now owns 3,707,445 shares of the company's stock valued at $27,620,000 after acquiring an additional 1,783,765 shares during the period. Geode Capital Management LLC boosted its stake in shares of EyePoint Pharmaceuticals by 28.3% in the 4th quarter. Geode Capital Management LLC now owns 1,538,902 shares of the company's stock valued at $11,467,000 after purchasing an additional 339,846 shares in the last quarter. Finally, Finepoint Capital LP grew its holdings in shares of EyePoint Pharmaceuticals by 57.1% in the 4th quarter. Finepoint Capital LP now owns 1,111,104 shares of the company's stock worth $8,278,000 after purchasing an additional 403,700 shares during the last quarter. Institutional investors and hedge funds own 99.41% of the company's stock.

EyePoint Pharmaceuticals Stock Performance

NASDAQ EYPT traded down $0.09 on Wednesday, reaching $6.16. The company had a trading volume of 271,534 shares, compared to its average volume of 840,084. The company's fifty day moving average is $6.02 and its 200-day moving average is $7.59. The firm has a market capitalization of $423.67 million, a price-to-earnings ratio of -3.06 and a beta of 1.58. EyePoint Pharmaceuticals, Inc. has a 1-year low of $3.91 and a 1-year high of $13.99.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.65). EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. The business had revenue of $24.50 million for the quarter, compared to analyst estimates of $8.84 million. On average, research analysts forecast that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on EYPT shares. Citigroup initiated coverage on shares of EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They issued a "buy" rating and a $33.00 price target on the stock. StockNews.com raised EyePoint Pharmaceuticals to a "sell" rating in a report on Friday, March 14th. HC Wainwright reaffirmed a "buy" rating and issued a $22.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. Finally, Chardan Capital reissued a "buy" rating and set a $33.00 price objective on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. One research analyst has rated the stock with a sell rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $26.63.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.